Valeant Pharma (VRX) Reports Q2 EPS of $1.91
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Valeant (VRX) Price Target Reduced at Deutsche Bank
July 31, 2014 3:08 PM EDTDeutsche Bank maintained a Hold rating on Valeant Pharmaceuticals (NYSE: VRX) and reduced its price target to $128.00 (from $133.00). The change follows its Q2 report. Analyst Gregg Gilbert described results as "ho-hum."
"While EPS of $1.91 came in line with our estimate (helped by lower tax rate), gross margin, operating income, and cash flow came in under our... More
Valeant Pharma (VRX) price drop a buying opportunity, Bill Ackman tells CNBC
July 31, 2014 12:19 PM EDTValeant Pharma (NYSE: VRX) price drop a buying opportunity, Bill Ackman tells CNBC. Shares are down nearly 7.6% following results.
... More